AI
Monday, April 04, 2011 1:09:07 PM
OREX showing some life,
any chance to close the gap above?
Vivus Inc. (VVUS) said a two-year study found its weight-loss drug Qnexa also reduces blood pressure and the required use of antihypertension medications, while rival Orexigen Therapeutics Inc. (OREX) said a separate one-year study showed patients using its obesity drug Contrave maintained normal blood pressure levels for a 24-hour period.
Vivus shares surged 10% at $6.95 premarket. As of Friday's $6.31 close, the stock had fallen 33% so far this year. Orexigen shares got a 7.6% bump to $3.10. As of Friday's $2.88 close, the stock had fallen 64% so far this year.
Long-term data from Vivus's Sequel study showed that patients who received the top dose had sustained weight loss greater than 10% over two years. This weight loss led to reductions in blood pressure and triglyceride while improving lipid levels.
any chance to close the gap above?
Vivus Inc. (VVUS) said a two-year study found its weight-loss drug Qnexa also reduces blood pressure and the required use of antihypertension medications, while rival Orexigen Therapeutics Inc. (OREX) said a separate one-year study showed patients using its obesity drug Contrave maintained normal blood pressure levels for a 24-hour period.
Vivus shares surged 10% at $6.95 premarket. As of Friday's $6.31 close, the stock had fallen 33% so far this year. Orexigen shares got a 7.6% bump to $3.10. As of Friday's $2.88 close, the stock had fallen 64% so far this year.
Long-term data from Vivus's Sequel study showed that patients who received the top dose had sustained weight loss greater than 10% over two years. This weight loss led to reductions in blood pressure and triglyceride while improving lipid levels.
My post is for my own entertainment, do your own DD
before pushing your buy/sell buttons
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
